A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Non-small Cell Lung Cancer (NSCLC) in the Advanced and Adjuvant Settings
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs VAC 2 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- 12 Nov 2019 According to a Lineage Cell Therapeutics media release, immunogenicity data from the initial patients in this trial is expected by year end 2019.
- 31 Jul 2019 According to an BioTime media release, the company has changed its name to Lineage Cell Therapeutics, Inc.
- 27 Nov 2018 According to an Asterias Biotherapeutics media release, the company is planning to open the third site in this study.